Document Classification

Section Type: RESULTS

Text: Patients with mild AD in the 800 mg tarenflurbil group had lower rates of decline than did those in the placebo group in activities of daily living (ADCS-ADL difference in slope 3. 98 [95 % CI 0. 33 to 7. 62] points per year, effect size [reduction from placebo decline rate] 46. 4 %, Cohen 's d 0. 45 ; p = 0. 033) and global function (CDR-sb difference -0. 80 [-1. 57 to -0. 03] points per year, effect size 35. 7 %, Cohen 's d 0. 42 ; p = 0. 042) ; slowing of cognitive decline did not differ significantly (ADAS-cog difference -1. 36 [-4. 07 to 1. 36] points per year, effect size 33. 7 %, Cohen 's d 0. 20 ; p = 0. 327).